Investors

  • 2022-09-30
    DALAY IN DESPATCH OF CIRCULAR
  • 2022-09-19
    (1) GRANT OF OPTIONS (2) NON-EXEMPT CONNECTED TRANSACTION — PROPOSED AWARD GRANT TO A CONNECTED PERSON (3) NON-EXEMPT CONNECTED TRANSACTION — PROPOSED PERFORMANCE TARGET AWARD GRANT TO A CONNECTED PERSON
  • 2022-09-19
    APPOINTMENT OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER
  • 2022-09-01
    NOTIFICATION LETTER WITH REQUEST FORM TO NON-REGISTERED HOLDERS
  • 2022-09-01
    NOTIFICATION LETTER WITH CHANGE REQUEST FORM TO REGISTERED SHAREHOLDERS
  • 2022-08-26
    RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER
  • 2022-08-24
    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2022
  • 2022-08-24
    CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG
  • 2022-08-16
    (1) MAJOR TRANSACTION IN RELATION TO THE TERMINATION AND TRANSITION SERVICES AGREEMENT AND (2) CHANGE IN USE OF PROCEEDS FROM THE GLOBAL OFFERING
  • 2022-08-12
    Date of Board Meeting
 Copyright Everest Medicines 2020  云顶药业(苏州)有限公司 苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers

沪公网安备 31010602006477号